股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 2. 股份分類 ...

Town Health International Medical Group Limited 康健國際 醫 療 集 團 有限公司 （ 於 開 曼 群 島 註 冊 成 立 及 於 百 慕 達 存 續 之 有 限 公 司 ） （ 股份代號 ： 3 8 8 6 ） （ 「 本 公 司 」 ） 提名委員會之職權範圍 （生效日期：2026 年 1 月 1 日） 1. 目標 提名委員會（「委員會」）負 責 向 本公 司 董事 會（「董事會」）建議委任本公司的董 事（「董事」），以確保所有提名屬公平及具透明度。 2. 組成 3. 會議 2.1 委員會須由董事會委任，並由最少三名成員組成。當中大部分成員須為本 公司的獨立非執行董事。委員會至少一名成員須為不同性別的成員。 2.2 委員會的主席須由董事會委任，並須為董事會主席或獨立非執行董事。 2.3 委員會的秘書須由本公司的公司秘書擔任，秘書必須確保所有會議均能 保存完整的會議記錄。 3.1 委員會舉行的會議和會議議程，須受本公司細則關於董事會會議和議程 的適用條文所管轄。 3.2 委員會每年須舉行至少一次會議，並於有需要時或任何委員會成員要求 時舉行會議。委員會會議的法定 ...

Core Viewpoint - The article highlights the launch of a public respiratory health education project by 康健国际医疗 in collaboration with Pfizer Hong Kong and Tung Wah Group of Hospitals, aimed at enhancing community health protection against respiratory diseases, particularly pneumonia, during the high-risk winter season [1][2]. Group 1: Project Overview - 康健国际医疗, Pfizer Hong Kong, and Tung Wah Group of Hospitals have established a collaborative framework to enhance public health education and provide accessible vaccination services [2]. - The project includes a donation of 20-valent pneumococcal conjugate vaccines to support vulnerable communities, aligning with the Hong Kong Department of Health's "prevention first" strategy [1][2]. Group 2: Health Statistics and Risks - Pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths projected in 2024, highlighting the urgent need for preventive measures [2]. - The pneumococcus bacterium poses significant treatment challenges due to increasing antibiotic resistance, necessitating a focus on prevention [4]. Group 3: Vaccine Details - The donated 20-valent pneumococcal conjugate vaccine covers 20 serotypes, including seven newly added types associated with high mortality and antibiotic resistance [2]. - A single dose of the vaccine provides broad protection, particularly for high-risk groups such as the elderly and those with chronic illnesses [2]. Group 4: Community Impact - The initiative addresses health protection gaps for economically disadvantaged and mobility-impaired individuals, ensuring equitable access to vaccination [4]. - The project aims to shift public health perspectives from treatment-focused to prevention-oriented approaches, enhancing community awareness of pneumonia risks and vaccine benefits [5]. Group 5: Collaborative Model - The partnership exemplifies a successful integration of commercial healthcare services, pharmaceutical expertise, and community outreach, creating a comprehensive prevention and support system [5]. - This model serves as a replicable framework for future public health initiatives, potentially alleviating the overall burden on Hong Kong's public healthcare system [5].

Core Viewpoint - The article highlights the launch of a public respiratory health education project by 康健国际医疗 in collaboration with Pfizer Hong Kong and Tung Wah Group of Hospitals, aimed at enhancing community health protection against respiratory diseases, particularly pneumonia, during the high-risk winter season [1][2]. Group 1: Project Overview - The initiative is a response to the Hong Kong Department of Health's "Primary Healthcare Blueprint," promoting a shift from treatment-focused to prevention-oriented health concepts [2]. - 康健国际医疗 will coordinate public health education and provide vaccination services through its extensive network, while Pfizer will supply the 20-valent pneumococcal conjugate vaccine and medical expertise [2]. - Tung Wah Group of Hospitals will identify and assist vulnerable communities to ensure effective vaccine distribution and administration [2]. Group 2: Health Statistics and Vaccine Details - Pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths projected in 2024, making it a significant public health concern [3]. - The 20-valent pneumococcal conjugate vaccine covers 20 serotypes, including seven newly added types associated with high mortality and antibiotic resistance, requiring only one dose for broad protection [3]. Group 3: Community Impact and Collaboration - The project addresses the urgent need for respiratory health education, particularly for the elderly and vulnerable populations, who face higher infection risks [4]. - The collaboration aims to fill the health protection gap for economically disadvantaged groups, allowing them to receive the vaccine for free [5]. - The initiative exemplifies a comprehensive approach to public health, integrating commercial healthcare services, pharmaceutical expertise, and community outreach to enhance the effectiveness of health interventions [6]. Group 4: Health Awareness and Future Implications - The project promotes a shift in public health perception from treatment to prevention, enhancing community awareness of pneumonia risks and the value of vaccination [6]. - The collaboration model serves as a reference for future public health initiatives, potentially applicable to chronic disease management and other infectious disease control efforts [6].

Core Viewpoint - 康健国际医疗 collaborates with Pfizer Hong Kong to promote respiratory health education and provide 20-valent pneumococcal conjugate vaccines to underprivileged communities in Hong Kong [1][2] Group 1: Collaboration and Initiatives - 康健国际医疗, through its charity fund, donates a batch of 20-valent pneumococcal conjugate vaccines to the Tung Wah Group of Hospitals for community health protection [1] - The partnership aims to shift public health perception from "treatment-based" to "prevention-based" [1][2] - The extensive network of medical centers across Hong Kong will facilitate public access to the vaccines [1] Group 2: Public Health Impact - Pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths in 2024, making it more lethal than heart disease and cerebrovascular diseases [4] - Pneumococcal infections pose a significant public health threat, particularly to the elderly and vulnerable populations [3][4] - Vaccination is highlighted as the most effective method to prevent pneumococcal diseases, significantly reducing the risk of invasive infections and severe outcomes [4] Group 3: Community Engagement - The Tung Wah Group of Hospitals will play a crucial role in distributing the donated vaccines and identifying suitable beneficiaries for vaccination [1][2] - The collaboration emphasizes the importance of community health investment and aims to alleviate the disease burden on vulnerable groups [3]

Group 1 - 康健国际医疗 collaborates with Pfizer Hong Kong to promote respiratory health education and donate 20-valent pneumococcal conjugate vaccines to underprivileged communities through the 康健慈善基金 [1] - The initiative aims to shift public health perspectives from "treatment-based" to "prevention-based" in response to the Hong Kong Department of Health's "Primary Healthcare Blueprint" [1] - The partnership with 东华三院 will ensure proper distribution of the donated vaccines to eligible individuals within the community [1][2] Group 2 - The chairman and CEO of 康健医疗 emphasized the public health threat posed by pneumococcal infections, particularly among the elderly and vulnerable groups, highlighting the urgency of respiratory health education [2] - According to the latest statistics from the Department of Health, pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths in 2024, making it more lethal than heart disease and cerebrovascular diseases [4] - Vaccination against pneumococcal disease is identified as one of the most effective preventive measures, significantly reducing the risk of invasive infections and severe illness [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,0 ...

Core Viewpoint - 康健国际医疗 (03886) has transferred shares worth HKD 181 million from UBS Securities Hong Kong Limited to DBS Bank Hong Kong, representing 10.48% of the total shares [1] Financial Performance - For the six months ending in 2025, 康健国际医疗 reported revenue of HKD 901 million, a year-on-year decrease of 1.46% [1] - The company achieved a profit attributable to shareholders of HKD 12.727 million, compared to a loss of HKD 47.676 million in the same period last year, indicating a turnaround to profitability [1] - Basic earnings per share were reported at HKD 0.19 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 2. 股份分類 | 優先股 | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,00 ...